CorMedixCRMD
CRMD
About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Employees: 82
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
257% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 14
185% more capital invested
Capital invested by funds: $146M [Q1] → $418M (+$271M) [Q2]
88% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 33
23% more funds holding
Funds holding: 136 [Q1] → 167 (+31) [Q2]
13.57% more ownership
Funds ownership: 36.42% [Q1] → 49.99% (+13.57%) [Q2]
11% more call options, than puts
Call options by funds: $6.11M | Put options by funds: $5.51M
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
22%
upside
Avg. target
$18
29%
upside
High target
$20
43%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Brandon Folkes | 22%upside $17 | Buy Maintained | 8 Aug 2025 |
Needham Serge Belanger | 43%upside $20 | Buy Maintained | 24 Jun 2025 |
RBC Capital Leonid Timashev | 22%upside $17 | Outperform Reiterated | 20 Jun 2025 |
Financial journalist opinion
Based on 11 articles about CRMD published over the past 30 days
Positive
Seeking Alpha
10 hours ago
CorMedix: The Undervalued Breakthrough
CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 week ago
Why CorMedix (CRMD) Might be Well Poised for a Surge
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neutral
Seeking Alpha
2 weeks ago
CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript
CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Participants Anish Nikhanj - RBC Capital Markets, Research Division Brandon Richard Folkes - H.C.
Positive
WSJ
2 weeks ago
CorMedix to Buy Melinta Therapeutics for $300 Million
The buyer said the deal adds six marketed infectious-disease products to its offerings.
Positive
Zacks Investment Research
2 weeks ago
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.
Neutral
Business Wire
2 weeks ago
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership.
Neutral
GlobeNewsWire
2 weeks ago
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.
Neutral
GlobeNewsWire
2 weeks ago
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million Pro forma 2025 combined revenues estimated to be $305 to $335 million Advances CorMedix's strategy to build a formidable specialty pharmaceutical business through a combination of organic and inorganic growth Dynamic platform can be leveraged to support additional products and expand as the combined company enters its next phase CorMedix to host conference call and webcast today at 8:30 a.m. ET. BERKELEY HEIGHTS, N.J.
Positive
Zacks Investment Research
2 weeks ago
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™